生物科技公司莫德纳（Moderna，股票代码：MRNA）今日股价表现强劲，盘中大涨5.03%。这一显著涨幅主要源于公司在新冠疫苗领域的最新进展。
据报道，莫德纳宣布其针对SARS-CoV-2变异株LP.8.1的更新版新冠疫苗已获得加拿大卫生部正式批准。这款名为Spikevax的mRNA疫苗可用于6个月及以上年龄人群。公司表示，针对LP.8.1变异株的疫苗剂量预计将于今年秋季在加拿大市场推出。
这一批准不仅扩大了莫德纳在加拿大市场的影响力，也增强了投资者对公司未来业绩的信心。值得注意的是，莫德纳的更新版新冠疫苗此前已获得欧洲、日本、瑞士等国家和地区监管机构的批准，显示出公司在全球疫苗市场的竞争力。此外，莫德纳表示有望在2025-2026年疫苗接种季及时提供更新疫苗，进一步巩固了其在新冠疫苗领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.